Ovarian stimulation protocol in IVF: An up-to-date review of the literature

Current Pharmaceutical Biotechnology

Volumn 17, Issue 4, 2016, Pages 303-315

  Pacchiarotti, Alessandro ^b   Selman, Helmy ^c   Valeri, Claudia ^b   Napoletano, Simona ^a   Sbracia, Marco ^b   Antonini, Gabriele ^a,b   Biagiotti, Giulio ^b   Pacchiarotti, Arianna ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Praxis Ds   (Italy)

^c Doha Clinic Hospital   (Qatar)

Author keywords

Antioxidant; Embryo; FSH; GnRH analogues; Implantation; Oocyte ovarian stimulation ovarian triggering; Pregnancy

Indexed keywords

ANASTROZOLE; BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; CORIFOLLITROPIN ALFA; FERTIPEPTYL; FOLIC ACID; FOLLITROPIN; GANIRELIX; GONADORELIN; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; INOSITOL; LEUPRORELIN; MELATONIN; MUELLERIAN INHIBITING FACTOR; PRASTERONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; TRIPTORELIN; UNCLASSIFIED DRUG; UROFOLLITROPIN; HORMONE ANTAGONIST;

ANTRAL FOLLICLE COUNT; ARTICLE; BIRTH RATE; DRUG EFFICACY; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; INTRAUTERINE INSEMINATION; META ANALYSIS (TOPIC); NIDATION; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUPPLEMENTATION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL SYSTEM PARAMETERS; DRUG EFFECTS; FEMALE; OOCYTE; PREGNANCY; PROCEDURES;

FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HORMONE ANTAGONISTS; HUMANS; OOCYTES; OVULATION INDUCTION; PREGNANCY;

EID: 84959859420     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201017666160118103147     Document Type: Article

References (86)

1. Flanagan, C. A.; Millar, R. P.; Illing, N. Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions. Rev. Reprod., 1998, 2(2), 113-120.
2. Jiang, X.; Liu, H.; Chen, X.; Chen, P. H.; Fischer, D.; Sriraman, V.; Yu, H. N.; Arkinstall, S.; He, X. Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor. Proc. Natl. Acad. Sci. USA, 2012, 109(31), 12491-12496.
3. Jiang, X.; Dias, J. A.; He, X. Structural biology of glycoprotein hormones and their receptors, insights to signaling. Mol. Cell. Endocrinol., 2014, 382(1), 424-451.
4. Knight, P. G.; Glister, C. TGF-beta superfamily members and ovarian follicle development. Reproduction, 2006, 132(2), 191-206.
5. Laufer, N.; Decherney, A. H.; Haseltine, F. P.; Polan, M. L.; Tarlatzis, B. C, Dlugi, A. M.; Naftolin, F. Human in vitro fertilization employing individualized ovulation induction by human menopausal gonadotropins. J. In Vitro Fert. Embryo Transf., 1984, 1(1), 56-62.
6. Chang, M. Y.; Chiang, C. H.; Hsieh, T. T.; Soong, Y. K.; Hsu, K. H.; Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil. Steril., 1998, 69(3), 505-510.
7. Durlinger, A. L. L.; Visser, J. A.; Themmen, A. P. N. Regulation of ovarian function, the role of anti-Mullerian hormone. Reproduction, 2002, 124, 601-609.
8. Lee, M. M.; Donahoe, P. K.; Hasegawa, T.; Silverman, B.; Crist, G. B.; Best, S.; Hasegawa, Y.; Noto, R. A.; Schoenfeld, D.; MacLaughlin, D. T. Mullerian inhibiting substance in humans, normal levels from infancy to adulthood. J. Clin. Endocrinol. Metab., 1996, 81(2), 571-576.
9. Visser, J. A.; de Jong, F. H.; Laven, J. S.; Themmen, A. P. Anti-Müllerian hormone, a new marker for ovarian function. Reproduction, 2006, 131(1), 1-9.
10. van Rooij, I. A.; Broekmans, F. J.; teVelde, E. R.; Fauser, B. C.; Bancsi, L. F.; de Jong, F. H.; Themmen, A. P. N. Serum anti-Mullerian hormone levels, a novel measure of ovarian reserve. Hum. Reprod., 2002, 17(12), 3065-3071.
11. Aboulghar, M.; Saber, W.; Amin, Y.; Aboulghar, M. M.; Serour, G.; Mansour, R. Impact of antimüllerian hormone assays on the outcomes of in vitro fertilization, a prospective controlled study. Fertil. Steril., 2014, 101(1), 134-137.
12. La Marca, A.; Sunkara, S. K. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers, From theory to practice. Hum. Reprod. Update, 2014, 20(1), 124-140.
13. Jolande, G. van der Stegea.; van der Lindenb P. J. Q. Useful predictors of ovarian stimulation response in women undergoing in vitro fertilization. Gynecol. Obstet. Invest., 2001, 52, 43-46.
14. Harris, I.; Missmer, S.; Hornstein, M. Poor success of gonadotropin-induced controlled ovarian hyperstimulation and intrauterine insemination for older women. Fertil. Steril., 2010, 94(1), 144-148.
15. Depalo, R.; Jayakrishan, K.; Garruti, G.; Totaro, I.; Panzarino, M.; Giorgino F.; Selvaggi, L. E. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reprod. Biol. Endocrinol., 2012, 13, 10-26.
16. Albano, C.; Smitz, J.; Camus, M.; Riethmüller-Winzen, H.; Van Steirteghem, A.; Devroey, P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil. Steril., 1997, 67(5), 917-922.
17. Diedrich, K.; Diedrich, C.; Santos, E.; Zoll, C.; al-Hasani, S.; Reissmann, T.; Krebs, D.; Klingmüller, D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophinreleasing hormone antagonist Cetrorelix during ovarian stimulation. Hum. Reprod., 1994, 9(5), 788-791.
18. Cota, A. M.; Oliveira, J. B.; Petersen, C. G.; Mauri, A. L.; Massaro, F. C.; Silva, L. F.; Nicoletti, A.; Cavagna, M.; Baruffi, R. L.; Franco, J. G. Jr. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: Oocyte morphology. Reprod. Biol. Endocrinol., 2012, 10, 33.
19. Gordts, S.; Van Turnhout, C.; Campo, R.; Puttemans, P.; Valkenburg, M.; Gordts, S. A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF. Facts Views Vis. Obgyn., 2012, 4(2), 82-87.
20. Xiao, J. S.; Su, C. M.; Zeng X. T. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF, a systematic review and meta-analysis. PLoS One, 2014, 9(9), e106854.
21. Pu, D.; Wu, J.; Liu, J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum. Reprod., 2011, 26, 2742-2749.
22. Chatillon-Boissier, K.; Genod, A.; Denis-Belicard, E.; Felloni, B.; Chene, G.; Seffert, P.; Chauleur, C. Prospective randomised study of long versus short agonist protocol with poor responder patients during in vitro fertilization, Gynecol. Obstet. Fertil., 2012, 40(11), 652-657.
23. Prapas, Y.; Petousis, S.; Dagklis, T.; Panagiotidis, Y.; Papatheodorou, A.; Assunta, I.; Prapas N. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders, a randomized clinical trial. Eur. J. Obstet. Gynecol. Reprod. Biol., 2013, 166(1), 43-46.
24. Sunkara, S. K.; Coomarasamy, A.; Faris, R.; Braude, P.; Khalaf, Y. Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization, a randomized controlled trial. Fertil. Steril., 2014, 101(1), 147-153.
25. Lainas, T. G.; Petsas, G. K.; Zorzovilis, I. Z.; Iliadis, G. S.; Lainas, G. T.; Cazlaris, H. E.; Kolibianakis, E. M. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: Effect on hormonal levels and follicular development. Hum. Reprod., 2007, 22(6), 1540-6.
26. Lainas T. G.; Sfontouris, I. A.; Zorzovilis, I. Z.; Petsas, G. K.; Lainas, G. T.; Alexopoulou, E.; Kolibianakis, E. M. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF, a prospective randomised controlled trial (RCT). Hum Reprod., 2010, 25(3), 683-689.
27. Tehraninejad, E. S.; Nasiri, R.; Rashidi, B.; Haghollahi, F.; Ataie, M. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOS patients. Arch. Gynecol. Obstet., 2010, 282, 319-325.
28. Thuesen, L. L.; Loft, A.; Egeberg, A. N.; Smitz, J.; Petersen, J. H.; Andersen, A. N. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Hum. Reprod., 2012, 27(10), 3074-3084.
29. Tan, S. L.; Child T. J.; Cheung, A. P.; Fluker, M. R.; Yuzpe, A.; Casper, R, Leung P.; Cadesky, K.; Davis, V. J. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment. J. Assist. Reprod. Genet., 2005, 22(2), 81-8.
30. Jayaprakasan, K.; Hopkisson, J.; Campbell, B.; Johnson, I.; Thornton, J.; Raine-Fenning, N. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. BJOG, 2010, 117(7), 853-862.
31. Brinsden, P.; Akagbosu, F.; Gibbons L. M.; Lancaster, Susan.; Gourdon, D.; Engrand, P.; Loumaye, E. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilizationembryo transfer. Fertil. Steril., 2000, 73(1), 114-116.
32. Platteau, P.; Laurent, E.; Albano, C.; Osmanagaoglu, K.; Vernaeve, V.; Tournaye, H.; Camus, M.; Van Steirteghem, A.; Devroey, P. An open, randomized single-centre study to compare the efficacy and convenience of follitropin beta administered by a pen device with follitropin alpha administered by a conventional syringe in women undergoing ovarian stimulation for IVF/ICSI. Hum. Reprod., 2003, 18(6), 1200-1204.
33. Al-Inany, H.; Aboulghar, M.; Mansour, R.; Serour, G. Metaanalysis of recombinant versus urinary-derived FSH, an update. Hum. Reprod., 2003, 18(2), 305-313.
34. Coomarasamy, A.; Afnan, M.; Cheema, D.; van der Veen, F.; Bossuyt, P. M.; van Wely, M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment, a systematic review and meta-analysis. Hum. Reprod., 2008, 23(2), 310-315.
35. Bosch, E.; Vidal, C.; Labarta, E.; Simon, C.; Remohi, J.; Pellicer, A. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists-a randomized study Hum. Reprod., 2008, 23(10), 2346-2351.
36. Ziebe, S.; Lundin, K.; Janssens, R.; Helmgaard, L.; Arce J. C. MERIT (Menotrophin vs Recombinant FSH in vitro Fertilisation Trial) Group. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Hum. Reprod., 2007, 22(9), 2404-2413.
37. Selman, H.; De Santo, M.; Sterzik, K.; Coccia, E.; El-Danasouri, I. Effect of highly purified urinary follicle stimulating hormone on oocyte and embryo quality. Fert. Steril., 78; 2002; 1061-1067.
38. Pacchiarotti, A.; Aragona, C.; Gaglione, R.; Selman, H. Efficacy of a combined protocol of urinary and recombinant folliclestimulating hormone used for ovarian stimulation of patients undergoing ICSI cycle. J. Assist. Reprod. Genet., 2007, 24(9), 400-405.
39. Selman, H.; Pacchiarotti, A.; El-Danasouri, I. Ovarian stimulation protocols based on follicle-stimulating hormone glycosylation pattern, impact on oocyte quality and clinical outcome. Fertil. Steril., 2010, 94(5), 1782-1786.
40. Selman, H.; Pacchiarotti, A.; Rinaldi, L.; Crescenzi, F.; Lanzilotti, G.; Lofino, S.; El-Danasouri, I. Simultaneous administration of human acidic and recombinant less acidic follicle-stimulating hormone for ovarian stimulation improves oocyte and embryo quality, and clinical outcome in patients with repeated IVF failures. Eur. Rev. Med. Pharmacol. Sci., 2013, 17(13), 1814-1819.
41. Pouwer, A. W.; Farquhar, C.; Kremer, J. A. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database Syst. Rev., 2012, 6, CD009577.
42. Mahmoud Youssef M. A.; van Wely, M.; Aboulfoutouh, I.; El-Khyat, W.; van der Veen F.; Al-Inany, H. Is there a place for corifollitropinalfa in IVF/ICSI cycles? A systematic review and metaanalysis. Fertil. Steril., 2012, 97(4), 876-885.
43. Blockeel, C.; Polyzos, N. P.; Derksen, L.; De Brucker, M.; Vloeberghs, V.; van de Vijver, A.; De Vos, M.; Tournaye, H. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol, a randomized controlled pilot study. Hum. Reprod., 2014, 29(7), 1500-1507.
44. Pacchiarotti, A.; Sbracia, M.; Frega, A.; Selman, H.; Rinaldi, L.; Pacchiarotti, A. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil. Steril., 2010, 94(6), 2467-9.
45. Durnerin, C. I.; Erb K.; Fleming, R.; Hillier, H.; Hillier, S. G.; Howles, C. M.; Hugues, J. N.; Lass, A.; Lyall, H.; Rasmussen, P.; Thong, J.; Traynor, I.; Westergaard, L.; Yates, R. Luveris Pretreatment Group. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum. Reprod., 2008, 23(2), 421-426.
46. Razi, M. H.; Mohseni, F.; Dehghani, F. R.; Janati, S.; Yari N.; Etebary, S. Results from adding recombinant LH for assisted reproductive technology treatment, A randomized control trial. Iran J. Reprod. Med., 2014, 12(2), 111-116.
47. Mohamed, M. A.; Sbracia, M.; Pacchiarotti, A.;, Micara, G.; Linari, A.; Tranquilli, D.; Espinola, S. M.; Aragona, C. Urinary folliclestimulating hormone (FSH) is more effective than recombinant FSH in older women in a controlled randomized study. Fertil. Steril., 2006, 85(5), 1398-1403.
48. Kolibianakis, E. M.; Venetis, C. A.; Bosdou, J. K.; Zepiridis, L.; Chatzimeletiou, K.; Makedos, A.; Masouridou, S.; Triantafillidis, S.; Mitsoli, A.; Tarlatzis, B. C. Corifollitropinalfa compared with follitropin beta in poor responders undergoing ICSI, a randomized controlled trial. Hum. Reprod., 2015, 30(2), 432-440.
49. Polyzos, N. P.; De Vos, M.; Corona, R.; Vloeberghs, V.; Ortega-Hrepich, C.; Stoop, D.; Tournaye, H. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders, a pilot study. Hum. Reprod., 2013, 28(5), 1254-1260.
50. König, T. E.; van der Houwen, LE, Overbeek, A.; Hendriks, M. L.; Beutler-Beemsterboer, S. N.; Kuchenbecker, W. K.; Renckens, C. N.; Bernardus, R. E.; Schats, R.; Homburg, R.;, Hompes, P. G.; Lambalk, C. B. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI, a randomized controlled multicentre study. Hum. Reprod., 2013, 28(10), 2804-2812.
51. Musters, A. M.; van Wely, M.; Mastenbroek, S.; Kaaijk, E. M.; Repping, S.; van der Veen, F.; Mochtar, M. H. The effect of recombinant LH on embryo quality, a randomized controlled trial in women with poor ovarian reserve. Hum. Reprod., 2012, 27(1), 244-250.
52. Barrenetxea, G.; Agirregoikoa, J. A.; Jiménez, M. R.; de Larruzea, A. L.; Ganzabal, T.; Carbonero, K. Ovarian response and pregnancy outcome in poor-responder women, a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil. Steril., 2008, 89(3), 546-553.
53. Yazıcı Yılmaz, F.; Görkemli, H.; Çolakoğlu, M. C.; Aktan, M.; Gezginç, K. The evaluation of recombinant LH supplementation in patients with suboptimal response torecombinant FSH undergoing IVF treatment with GnRH agonist down-regulation. Gynecol. Endocrinol., 2015, 31(2), 141-144.
54. Badawy, A.; Gibreal, A. Clomiphene citrate versus tamoxifen for ovulation induction in women with PCOS, a prospective randomized trial. Eur. J. Obstet. Gynecol. Reprod. Biol., 2011, 59(1), 151-154.
55. Daya, S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil. Steril., 2002, 77(4), 711-714.
56. Sipe, C. S.; Davis, W. A.; Maifeld, M.; Van Voorhis, B. J. A prospective randomized trial comparing anastrozole and clomiphene citrate in an ovulation induction protocol using gonadotropins. Fertil. Steril., 2006, 86(6), 1676-1681.
57. Figen, Turkcapar A.; Seckin, B.; Onalan, G.; Ozdener, T.; Batioglu, S. Human menopausal gonadotropin versus recombinant FSH in polycystic ovary syndrome patients undergoing in vitro fertilization. Int. J. Fertil. Steril., 2013, 6(4), 238-243.
58. Tarlatzis, B. C.; Griesinger, G.; Leader, A.; Rombauts, L.; Ijzerman-Boon, P. C.; Mannaerts, B. M. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. Reprod. Biomed Online, 2012, 24(4), 410-449.
59. Al-Inany, H. G.; Aboulghar, M.; Mansour, R.; Proctor, M. Recombinant versus urinary human chorionic gonadotrophin for ovulation induction in assisted conception. Cochrane Database Syst. Rev., 2005, (2), CD003719.
60. Decleer, W.; Osmanagaoglu, K.; Seynhave, B.; Kolibianakis. S.; Tarlatzis, B.; Devroey, P. Comparison of hCG triggering versus hCG in combination with a GnRH agonist, a prospective randomized controlled trial. Facts Views Vis. Obgyn., 2014, 6(4), 203-209.
61. Humaidan, P.; Polyzos, N. P.; Alsbjerg, B.; Erb, K.; Mikkelsen, A. L.; Elbaek, H. O.; Papanikolaou, E. G.; Andersen, C. Y. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation, two prospective randomized controlled multi-centre studies in IVF patients. Hum. Reprod., 2013, 28(9), 2511-2521.
62. Ferraretti, A. P.; La Marca, A.; Fauser B. C.; Tarlatzis B.; Nargund G.; Gianaroli L. ESHRE working group on poor ovarian response definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization, the Bologna criteria. Hum. Reprod., 2011, 26(7), 1616-1624.
63. Busnelli, A.; Papaleo, E.; Del Prato, D.; La Vecchia, I.; Iachini, E.; Paffoni, A.; Candiani, M.; Somigliana, E. A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria. Hum. Reprod., 2015, 30(2), 315-322.
64. Broer, S. L.; Dólleman, M.; Opmeer, B. C.; Fauser, B. C.; Mol, B. W.; Broekmans, F. J. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation, a meta-analysis. Hum. Reprod. Update, 2011, 17(1), 46-54.
65. Fallat, M. E.; Siow, Y.; Marra M, Cook, C.; Carrillo, A. Mullerian inhibiting substance in follicular fluid and serum, a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil. Steril., 1997, 67, 962-965.
66. Dewailly, D.; Andersen, C. Y.; Balen, A.; Broekmans, F.; Dilaver, N.; Fanchin, R.; Griesinger, G.; Kelsey, T. W.; La Marca, A.; Lambalk, C.; Mason, H.; Nelson, S. M.; Visser, J. A.; Wallace, W. H.; Anderson, R. A. The physiology and clinical utility of anti-Mullerian hormone in women. Hum. Reprod. Update, 2014, 20(3), 370-385.
67. Lee, T. H.; Liu, C. H.; Huang, C. C.; Wu, Y. L.; Shih, Y. T.; Ho, H. N.; Yang, Y. S.; Lee, M. S. Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum. Reprod., 2008, 23, 160-167.
68. Zaami, S.; Busardò, F. P. Elective egg freezing: Can you really turn back the clock? Eur. Rev. Med. Pharmacol. Sci., 2015, 19, XX.
69. Burger, H. G. Androgen production in women. Fertil. Steril., 2002, 77, S3-5.
70. Casson, P. R.; Lindsay, M. S.; Pisarska, M. D.; Carson, S. A.; Buster, J. E. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders, a case series. Hum. Reprod., 2000, 15, 2129-2132.
71. Singh, N.; Zangmo, R.; Kumar, S.; Roy, K. K.; Sharma, J. B.; Malhotra, N.; Vanamailv, P. A prospective study on role of dehydroepiandrosterone (DHEA) on improving the ovarian reserve markers in infertile patients with poor ovarian reserve. Gynecol. Endocrinol., 2013, 29(11), 989-992.
72. Poli, E.; Manfé, S.; Capuzzo, D.; Gava, S.; Viganò, F.; Coronella, M. L.; Gangemi, M. DHEA pre-treated patients, poor responders to a first IVF (ICSI) cycle, clinical results. Clin. Exp. Obstet. Gynecol., 2014, 41(1), 5-9.
73. Yeung, T. W.; Li, R.; H, Lee, V. C.; Ho, P. C.; Ng, E. H. A randomized double-blinded placebo-controlled trial on the effect ofdehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. J. Clin. Endocrinol. Metab., 2013, 98(1), 380-388.
74. Acuña-Castroviejo, D.; Escames, G.; Venegas, C.; Díaz-Casado, M. E.; Lima-Cabello, E.; López, L. C.; Rosales-Corral, S.; Tan, D. X.; Reiter, R. J. Extrapineal melatonin: Sources, regulation, and potential functions. Cell Mol. Life Sci., 2014, 71(16), 2997-3025.
75. Nakamura, Y.; Tamura, H.; Takayama, H.; Kato, H. Increased endogenous level of melatonin in preovulatory human follicles does not directly influence progesterone production. Fertil. Steril., 2003, 80, 1012-1016.
76. Fernando, S.; Rombauts, L. Melatonin, shedding light on infertility?-a review of the recent literature. J. Ovarian Res., 2014, 7, 98.
77. Eryilmaz, O.; Devran, A.; Sarikaya, E.; Aksakal, F.; Mollamahmutoğlu, L.; Cicek, N.; Melatonin improves the oocyte and the embryo in IVF patients with sleep disturbances, but does not improve the sleeping problems. J. Assist. Reprod. Genet., 2011, 28, 815-820.
78. Batıoğlu, A.; Şahin, U.; Gürlek, B.; Öztürk, N.; Ünsal, E. The efficacy of melatonin administration on oocyte quality. Gynecol. Endocrinol., 2012, 28, 91-93.
79. Nishihara, T.; Hashimoto, S.; Ito, K.; Nakaoka, Y.; Matsumoto, K.; Hosoi, Y.; Morimoto, Y. Oral melatonin supplementation improves oocyte and embryo quality in women undergoing in vitro fertilization-embryo transfer. Gynecol. Endocrinol., 2014, 30(5), 359-362.
80. Rizzo, P.; Raffone, E.; Benedetto, V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Embase European Rev. Med. Pharmacol. Sci., 2010, 14, 555-561.
81. Pacchiarotti, A.; Carlomagno, G.; Unfer, V.; Frati, P.; Pacchiarotti, A.; Prapas, N. Role of Myo-inositol and melatonin supplementation in follicular fluid of IVF patients with polycystic ovarian syndrome, a randomized controlled trial. ClinicalTrials. gov, 2013, NCT01540747.
82. Unfer, V.; Carlomagno, G.; Dante, G.; Facchinetti, F. Effects of myo-inositol in women with PCOS, a systematic review of randomized controlled trials. Gynecol. Endocrinol., 2012, 28(7), 509-515.
83. Lisi, F.; Carfagna, P.; Oliva, M. M.; Rago, R.; Lisi, R.; Poverini, R.; Manna, C.; Vaquero, E.; Caserta, D.; Raparelli, V.; Marci, R.; Moscarini, M. Pretreatment with myo-inositol in non-polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF, a pilotstudy. Reprod. Biol. Endocrinol., 2012, 23, 10-52.
84. Genazzani, A. D.; Santagni, S.; Rattighieri, E.; Chierchia, E.; Despini, G.; Marini, G.; Prati, A.; Simoncini, T. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol. Endocrinol., 2014, 30(6), 438-443.
85. Laganà, A. S.; Barbaro, L.; Pizzo, A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch. Gynecol. Obstet., 2014, 291(5), 1181-1186.
86. Pacchiarotti, A.; Valeri, C.; Antonini, G.; Biagiotti, G.; Prapas, N.; Pacchiarotti, A. Antioxidative capacity of melatonin in follicular fluid of aged IVF patients: Beneficial effects on oocytes and Embryos. J. Gyn. Neon Biol. 2(2), 1-5.